Abstract
Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain of PDGFRA. Olaratumab blocks ligand binding and thereby inhibits activation of PDGFRA kinase activity. Pre-clinically, this antibody inhibited PDGFRA-dependent tumor growth. In a randomized Phase II study, adding olaratumab to doxorubicin chemotherapy significantly improved overall survival, leading to FDA approval.
Original language | English (US) |
---|---|
Pages (from-to) | 555 |
Number of pages | 1 |
Journal | Cell |
Volume | 168 |
Issue number | 4 |
DOIs | |
State | Published - Feb 9 2017 |
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology